Table 1.
Sham (n = 10) | DOX + LacZ (n = 10) | DOX + sFas (n = 10) | |
---|---|---|---|
Heart weight (mg) | 95 ± 2.1 | 81 ± 4.3* | 83 ± 3.1* |
Body weight (g) | 26 ± 0.4 | 23 ± 0.7* | 22 ± 0.7* |
Heart to body weight ratio (mg/g) | 3.7 ± 0.06 | 3.6 ± 0.13 | 3.7 ± 0.17 |
Size of myocyte (μm) | 14.0 ± 0.2 | 12.3 ± 0.1* | 12.6 ± 0.3* |
CD45+ cells (/HPF) | 4.4 ± 0.28 | 7.6 ± 0.41* | 4.8 ± 0.34*† |
% fibrosis | 0.46 ± 0.02 | 1.04 ± 0.07* | 0.73 ± 0.06*† |
8-OHdG+ cells (/HPF) | 1.5 ± 0.1 | 16 ± 0.2* | 4.5 ± 0.1*† |
DOX, doxorubicin.
P < 0.05 versus the sham group.
P < 0.05 versus the LacZ-treated group.